Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma.

IF 4.3 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Frontiers in Bioengineering and Biotechnology Pub Date : 2024-11-13 eCollection Date: 2024-01-01 DOI:10.3389/fbioe.2024.1409988

Haoyu Wang, Haitian Jiang, Yining Tao, Binghui Yang, Jiakang Shen, Haoran Mu, Chongren Wang, Xiyu Yang, Zhengdong Cai, Mu Li, Wei Sun, Liu Yang, Mengxiong Sun

{"title":"Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma.","authors":"Haoyu Wang, Haitian Jiang, Yining Tao, Binghui Yang, Jiakang Shen, Haoran Mu, Chongren Wang, Xiyu Yang, Zhengdong Cai, Mu Li, Wei Sun, Liu Yang, Mengxiong Sun","doi":"10.3389/fbioe.2024.1409988","DOIUrl":null,"url":null,"abstract":"Introduction: Osteosarcoma, characterized by high mortality and disability rates, poses a significant challenge due to its complex genetic background and the absence of specific membrane receptors, which hinder effective targeted therapy. Active targeting has emerged as a promising approach to address this issue.Methods: In this study, magnetically driven hydrogel robots (MMHR) were utilized to load and deliver drugs precisely to target sites. The drugs included SCR1481B16, a specific MET inhibitor proven to inhibit MET-driven tumor growth, and Anlotinib. The microrobots were designed to navigate under magnetic guidance, enhancing drug efficacy while minimizing damage to normal tissues.Results: The study explored the potential of MMHR loaded with SCR1481B16 and Anlotinib in the treatment of Anlotinib-resistant osteosarcoma. The microrobots were successfully designed and produced, demonstrating the ability to deliver drugs precisely to tumor sites. Evaluation of the microrobots showed an enhanced sensitivity of tumors to Anlotinib, providing new insights into the treatment of drug-resistant osteosarcoma.Discussion: Tumors overexpressing MET often develop resistance to VEGFR-targeted drugs. The use of SCR1481B16 as a MET inhibitor in combination with Anlotinib, delivered by magnetically driven hydrogel microrobots, offers a novel strategy to overcome this resistance. However, further in-depth research and validation are required before the clinical application of this method can be considered.Conclusion: In conclusion, magnetically driven hydrogel microrobots loaded with SCR1481B16 provide a promising new strategy for enhancing the sensitivity of Anlotinib-resistant osteosarcoma, bringing hope for future clinical applications in the treatment of this challenging disease.","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"12 ","pages":"1409988"},"PeriodicalIF":4.3000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600141/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2024.1409988","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Osteosarcoma, characterized by high mortality and disability rates, poses a significant challenge due to its complex genetic background and the absence of specific membrane receptors, which hinder effective targeted therapy. Active targeting has emerged as a promising approach to address this issue.

Methods: In this study, magnetically driven hydrogel robots (MMHR) were utilized to load and deliver drugs precisely to target sites. The drugs included SCR1481B16, a specific MET inhibitor proven to inhibit MET-driven tumor growth, and Anlotinib. The microrobots were designed to navigate under magnetic guidance, enhancing drug efficacy while minimizing damage to normal tissues.

Results: The study explored the potential of MMHR loaded with SCR1481B16 and Anlotinib in the treatment of Anlotinib-resistant osteosarcoma. The microrobots were successfully designed and produced, demonstrating the ability to deliver drugs precisely to tumor sites. Evaluation of the microrobots showed an enhanced sensitivity of tumors to Anlotinib, providing new insights into the treatment of drug-resistant osteosarcoma.

Discussion: Tumors overexpressing MET often develop resistance to VEGFR-targeted drugs. The use of SCR1481B16 as a MET inhibitor in combination with Anlotinib, delivered by magnetically driven hydrogel microrobots, offers a novel strategy to overcome this resistance. However, further in-depth research and validation are required before the clinical application of this method can be considered.

Conclusion: In conclusion, magnetically driven hydrogel microrobots loaded with SCR1481B16 provide a promising new strategy for enhancing the sensitivity of Anlotinib-resistant osteosarcoma, bringing hope for future clinical applications in the treatment of this challenging disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

磁驱动水凝胶微型机器人用于增强安罗替尼对骨肉瘤的治疗效果。

简介骨肉瘤的特点是死亡率和致残率高，由于其复杂的遗传背景和缺乏特异性膜受体，阻碍了有效的靶向治疗，因此构成了一项重大挑战。主动靶向已成为解决这一问题的一种有前途的方法：在这项研究中，磁驱动水凝胶机器人（MMHR）被用来装载药物并精确地输送到靶点。这些药物包括 SCR1481B16（一种经证实可抑制 MET 驱动的肿瘤生长的特异性 MET 抑制剂）和安洛替尼。微型机器人的设计目的是在磁力引导下导航，在提高药物疗效的同时，尽量减少对正常组织的损伤：研究探索了装载有 SCR1481B16 和安罗替尼的 MMHR 治疗安罗替尼耐药骨肉瘤的潜力。微机器人的设计和生产获得了成功，证明了将药物精确输送到肿瘤部位的能力。对微机器人的评估显示，肿瘤对安罗替尼的敏感性增强，为耐药骨肉瘤的治疗提供了新的思路：讨论：过度表达MET的肿瘤通常会对血管内皮生长因子受体靶向药物产生耐药性。将 SCR1481B16 作为 MET 抑制剂与安罗替尼联合使用，通过磁驱动水凝胶微机器人递送，为克服这种耐药性提供了一种新策略。然而，在考虑这种方法的临床应用之前，还需要进一步的深入研究和验证：总之，装载了SCR1481B16的磁驱动水凝胶微机器人为提高安罗替尼耐药骨肉瘤的敏感性提供了一种前景广阔的新策略，为未来治疗这种具有挑战性疾病的临床应用带来了希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.